No abstract available
Keywords:
Crizotinib; HLA-DRB1-MET rearrangement; MET fusions; Non–small-cell lung cancer; Targeted treatments.
MeSH terms
-
Adenocarcinoma of Lung / drug therapy*
-
Adenocarcinoma of Lung / genetics
-
Adenocarcinoma of Lung / pathology
-
Crizotinib / administration & dosage*
-
Female
-
Gene Rearrangement
-
HLA-DRB1 Chains / genetics
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / genetics
-
Lung Neoplasms / pathology
-
Middle Aged
-
Protein Kinase Inhibitors / administration & dosage*
-
Proto-Oncogene Proteins c-met / genetics
-
Treatment Outcome
Substances
-
HLA-DRB1 Chains
-
Protein Kinase Inhibitors
-
Crizotinib
-
MET protein, human
-
Proto-Oncogene Proteins c-met